United States

NIH awards City of Hope $2.2M grant

Thursday, November 5, 2015

The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) has awarded a $2.2 million grant to help City of Hope researchers explore the underlying mechanisms of graft-versus-host disease, the leading cause of long-term sickness and death following transplantation of bone marrow cells from a donor. The grant, awarded to Defu Zeng, M.D., a professor of diabetes immunology and hematopoietic cell transplantation at the Beckman Research Institute of City of Hope, will be used by researchers to study the interactions of immune cells known as T cells and B cells during the development of GVHD.

[Read More]

FDA approves Imlygic

Thursday, November 5, 2015

Amgen has announced that the FDA has approved the Biologics License Application for Imlygic (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery. Imlygic has not been shown to improve overall survival or have an effect on visceral metastases. Imlygic is the first oncolytic viral therapy approved by the FDA based on therapeutic benefit demonstrated in a pivotal study.

[Read More]

Arena cuts 80 employees

Monday, November 2, 2015

Arena Pharmaceuticals, based in San Diego, has announced plans to improve efficiencies and reduce costs as it focuses on the advancement of its R&D priorities. As part of the initiative, Arena will reduce its U.S. workforce by about 80 employees or 35%, which Arena estimates will reduce annualized cash expenditures for personnel by about $11.0 million. Arena plans to implement additional cost control measures to further reduce its expenditures, including reductions at its Swiss manufacturing facility.

[Read More]

Amgen’s first-in-class oncolytic drug OK’d by FDA

Wednesday, October 28, 2015

The FDA has approved Amgen’s Biologics License Application for IMLYGIC (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery. [Read More]